<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content

    Live Webinar - Targeted Protein Degradation: New Modalities and Techniques

    Thursday, June 20, 2024, at 8:00 AM (PDT) 11:00 AM Eastern (EDT) 4:00 PM (BST)

    Reserve Your Webinar Seat
    Join us for an enlightening journey into the world of new modalities and technologies for targeted protein degradation.  Scheduled for June 20th, this event promises to be a melting pot of ideas featuring renowned experts Bernhard Fasching and Benedict Cross. Whether you're a seasoned researcher or new to the field, this webinar will deepen your understanding of targeted protein degradation and its potential impact on drug discovery and development.

    bernhard_fasching BenedictCross-1

    Bernhard Fasching, PhD

    VP Chemistry,
    Monte Rosa Therapeutics

    Benedict Cross, PhD

    CTO, 
    PhoreMost Therapeutics

    Speaker Biographies

    Bernhard Fasching graduated from the University of Dortmund and the Max Planck Institute for Kohlenforschung in 2007 in Total Synthesis with Prof. Fuerstner followed by a Post-Doc experience at Memorial Sloan Kettering working on glycopeptide synthesis with Prof. Danishefsky. Ever since, he has been working on the discovery and development of novel pharmacologically active molecules and principles for Hoffmann-La Roche and for a number of biotech companies in the areas of neuroscience, oncology and rare diseases. He has successfully lead drug discovery programs, using medicinal chemistry to advance molecules to patients. More recently, he has put a focus on the creation of biotech platforms centered around novel modes of action such as molecular glue degraders. Currently he is the head of chemistry at Monte Rosa Therapeutics leading the medicinal chemistry teams in drug discovery as well as the platform group with the aim to understand and employ the molecular mechanisms of ternary complex induction by small molecule drugs.

    Benedict Cross is the Chief Technology Officer at PhoreMost, a drug discovery company based in Cambridge, UK. He is a pioneer in the use of programmed mini-protein perturbagens to uncover new drug targets and has applied this in the protein degradation field in particular. Ben's research interests are in protein biogenesis, proteostasis, TPD and functional genomics screening.

    Key Discussion Points:

    1. Promising new modalities in drug discovery that are gaining traction in the pharmaceutical industry.
    2. Strategies and technologies being developed to improve outlook for "undruggable targets" associated with various diseases.

    Registration: Reserve your seat now to be part of this enlightening conversation. 

    Enter your email address to reserve your FREE webinar seat now. 

    Can't make it to the live webinar? Register to receive link to the on-demand recording.

    Reserve Your Seat For The Webinar